Cambridge Raman Imaging Ltd.

19/03/2022

16/02/2022

🚀🚀🚀

CHARM è il progetto che vuole sviluppare un dispositivo medico basato sulla tecnologia dell’imaging Raman digitale, caratterizzato da bassi costi e alte performance, e sull'intelligenza artificiale che potrebbe rivoluzionare la diagnosi e il trattamento del cancro.

10/02/2022

Un progetto coordinato da Cambridge Raman Imaging (CRI) è stato selezionato per ricevere una sovvenzione di 3,3 milioni di euro nell'ambito del programma europeo EIC Transition del Consiglio europeo per l'innovazione. CHARM mira a sviluppare un dispositivo medico basato sulla tecnologia dell’imag...

10/02/2022

Cambridge Raman Imaging will coordinate the CHARM project selected to receive a €3.3 million grant in the prestigious European Innovation Council’s (EIC) Transition Challenges call.

The project aims to develop a medical device based on high-speed, low-cost Raman digital imaging technology and artificial intelligence to transform cancer diagnosis and treatment. The technology will analyse the molecular composition of patient tissue samples to distinguish cancerous from healthy cells without the need for chemical staining.

CHARM will be coordinated by our CTO Matteo Negro and will be carried out by a consortium including Politecnico di Milano, CNR - IFN, Istituto di Fotonica e Nanotecnologie, Universitätsklinikum Jena, University of Cambridge, Inspiralia, IN srl.

Cambridge Raman Imaging (“CRI” or the “Company”) announces today it will coordinate a project selected to receive a €3.3 million grant in the European Innovation Council’s (EIC) Transition call.

21/05/2021

We've launched our brand new website. Check it out now

Coherent Raman Imaging Label-free chemometric imaging for objective, AI-assisted cell analysis and tissue diagnosis CRI brings together ultra-fast fibre based lasers and Coherent Raman scattering microscopy to make high-speed truly label free imaging possible, scanning tumour in seconds. Learn more....

01/12/2020

Cambridge Raman Imaging Ltd. and Cambridge Raman Imaging S.r.l. will be part of the consortium and commercial exploitation partner of 🚀CRIMSON project (https://lnkd.in/dAY-er5), funded by the European Commission with >5M€ budget 💲. This 3.5-years endeavor is aimed at developing an innovative 💡 bio-photonics device based on coherent vibrational for .

It will combine with data analysis for cell and tissue classification with unprecedented biomolecular sensitivity.

The project will be coordinated by Politecnico di Milano

The consortium:

✔ Technological partners: Leibniz-Institut für Photonische Technologien and CNRS - Institut Fresnel
✔ Biomedical partners to validate the imaging system on open biological questions related to : Fondazione IRCCS Istituto Nazionale dei Tumori, Inserm Institut National de la Sante et recherche medicale, Universitätsklinikum JenaU
✔ SME companies to commercially exploit the innovation: Active Fiber Systems GmbH, Lightcore, Cambridge Raman Imaging Ltd./Cambridge Raman Imaging S.r.l. and 3rdPlace | user & customer AI


Fisica - Politecnico di Milano

https://www.youtube.com/watch?v=NEtjOCjNe2s&feature=emb_logo

Brief presentation of the H2020 "CRIMSON" project: COHERENT RAMAN IMAGING FOR THE MOLECULAR STUDY OF THE ORIGIN OF DISEASES